Investigating new and future therapies for managing inflammatory bowel disease
by First Hospital of Jilin UniversityAntitumour necrosis factor alpha (anti-TNFα) agents include infliximab, adalimumab, golimumab, AVX-470 and OPRX-106. Janus kinase (JAK) inhibitors: tofacitinib, fi
Updated on: January 25,2024
Investigating new and future therapies for managing inflammatory bowel disease
by First Hospital of Jilin UniversityAntitumour necrosis factor alpha (anti-TNFα) agents include infliximab, adalimumab, golimumab, AVX-470 and OPRX-106. Janus kinase (JAK) inhibitors: tofacitinib, fi
Updated on:January 25,2024
